We are live on ! Find out more
BBC icon

Virtus Biotech Clinical Trials ETF
BBC

14 hedge funds and large institutions have $3.78M invested in Virtus Biotech Clinical Trials ETF in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

17% more funds holding

Funds holding: 12 → 14 (+2)

2% more capital invested

Capital invested by funds: $3.71M → $3.78M (+$68.7K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
14
Holders Change
+2
Holders Change %
+16.67%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$316K
2
Jane Street
Jane Street
New York
+$305K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$169K
4
SG Americas Securities
SG Americas Securities
New York
+$165K
5
MFS
MSI Financial Services
Massachusetts
+$20K

Top Sellers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
-$460K
2
VKH
Virtu KCG Holdings
New York
-$213K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$125K
4
UBS Group
UBS Group
Switzerland
-$9K
5
LTFS
Ladenburg Thalmann Financial Services
Florida
-$3.92K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$1.8M – – –
LPL Financial
2
LPL Financial
California
$446K -$460K -23,454 -50%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$321K -$125K -6,393 -26%
Citadel Advisors
4
Citadel Advisors
Florida
$291K +$316K +16,139 New
Jane Street
5
Jane Street
New York
$280K +$305K +15,532 New
Royal Bank of Canada
6
Royal Bank of Canada
Ontario, Canada
$190K +$169K +8,601 +440%
SG Americas Securities
7
SG Americas Securities
New York
$151K +$165K +8,400 New
SG
8
Societe Generale
$151K +$165K +8,400 New
LTFS
9
Ladenburg Thalmann Financial Services
Florida
$77K -$3.92K -200 -4%
Morgan Stanley
10
Morgan Stanley
New York
$25K – – –
MFS
11
MSI Financial Services
Massachusetts
$25K +$20K +1,020 +268%
Creative Planning
12
Creative Planning
Kansas
$16K – – –
MPWT
13
MassMutual Private Wealth & Trust
Connecticut
$4.46K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$1K -$1.96K -100 -55%
VKH
15
Virtu KCG Holdings
New York
– -$213K -11,163 Closed
UBS Group
16
UBS Group
Switzerland
– -$9K -458 Closed

BBC Hedge Fund Activity: Q2 2016 in Review

14 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q2 2016, worth a combined $3.78M — up 1.9% from $3.71M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BBC positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $316K. The largest seller was LPL Financial, cutting an estimated $460K.

  • 14 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q2 2016, up from 12 in Q1 2016.
  • Funds reported $3.78M of Virtus Biotech Clinical Trials ETF stock for Q2 2016, up 1.9% quarter-over-quarter.
  • 4 funds opened new Virtus Biotech Clinical Trials ETF positions in Q2 2016 and 2 closed out, a net change of +2 holders.
  • The largest Virtus Biotech Clinical Trials ETF buyer in Q2 2016 was Citadel Advisors, an estimated $316K added.
  • The largest Virtus Biotech Clinical Trials ETF seller in Q2 2016 was LPL Financial, an estimated $460K sold.

Based on aggregated 13F filings for Q2 2016.